These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1291 related items for PubMed ID: 27378175

  • 1. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL, Chang YC, Ko HL, Chi MS, Wang HE, Hsu PS, Lin CC, Yeh DY, Kao SJ, Jiang JS, Chi KH.
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [Abstract] [Full Text] [Related]

  • 2. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, Saka H, Kurata T, Nishimura Y, Fukuoka M.
    Cancer; 2012 Dec 15; 118(24):6126-35. PubMed ID: 22674529
    [Abstract] [Full Text] [Related]

  • 3. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M.
    J Clin Oncol; 2015 Dec 10; 33(35):4194-201. PubMed ID: 26527789
    [Abstract] [Full Text] [Related]

  • 4. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feldman L, Howard A, Abdelhady K, Weichselbaum RR, Virgo KS.
    J Thorac Oncol; 2013 Jul 10; 8(7):915-22. PubMed ID: 23608815
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M, Dominello M, Dyson G, Gadgeel S, Wozniak A, Miller S, Paximadis P.
    Clin Lung Cancer; 2017 Jan 10; 18(1):e21-e26. PubMed ID: 27567356
    [Abstract] [Full Text] [Related]

  • 6. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 7. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
    Mertsoylu H, Köse F, Sümbül AT, Sedef AM, Doğan Ö, Besen AA, Parlak C, Fındıkçıoğlu A, Muallaoğlu S, Sezer A, Sakallı H, Özyılkan Ö.
    Med Sci Monit; 2015 Mar 03; 21():661-6. PubMed ID: 25731741
    [Abstract] [Full Text] [Related]

  • 8. Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.
    Nawrocki S, Krzakowski M, Wasilewska-Tesluk E, Kowalski D, Rucinska M, Dziadziuszko R, Sowa A.
    J Thorac Oncol; 2010 Aug 03; 5(8):1255-62. PubMed ID: 20592630
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ.
    Clin Lung Cancer; 2013 Jul 03; 14(4):418-24. PubMed ID: 23291258
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world Prognostic Data on Unresectable Stage III Non-small-cell Lung Cancer Treated with Concurrent Chemoradiation Therapy by Histological Type.
    Toriyama K, Yomota M, Asai M, Hashimoto K, Mirokuji K, Kawai S, Watanabe K, Narita K, Hosomi Y.
    Intern Med; 2024 Oct 15; 63(20):2757-2765. PubMed ID: 38346736
    [Abstract] [Full Text] [Related]

  • 12. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y, Kim TH, Cho KH, Han JY, Lee YJ, Yun T, Kim HT, Lee JS.
    Radiat Oncol; 2014 Dec 13; 9():283. PubMed ID: 25498887
    [Abstract] [Full Text] [Related]

  • 13. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S, Li T, Lu B, Wang X, Li J, Chen M, Lu Y, Bai Y, Hu Y, Ouyang W, Ma Z, Li Q, Li H, Wang Y.
    Int J Radiat Oncol Biol Phys; 2015 Nov 15; 93(4):769-77. PubMed ID: 26530745
    [Abstract] [Full Text] [Related]

  • 14. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.
    Cancer; 1996 Jun 01; 77(11):2393-9. PubMed ID: 8635112
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy.
    Kurtul N, Eroglu C, Unal D, Tasdemir EA, Orhan O, Zararsiz G, Baran M, Kaplan B, Kontas O.
    Asian Pac J Cancer Prev; 2014 Jun 01; 15(20):8911-6. PubMed ID: 25374228
    [Abstract] [Full Text] [Related]

  • 16. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D, Bozcuk H, Gunduz S, Tural D, Tattli AM, Uysal M, Goksu SS, Bassorgun Cİ, Koral L, Coskun HS, Ozdogan M, Savas B.
    Asian Pac J Cancer Prev; 2014 Jun 01; 15(6):2465-72. PubMed ID: 24761848
    [Abstract] [Full Text] [Related]

  • 17. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
    Phernambucq EC, Hartemink KJ, Smit EF, Paul MA, Postmus PE, Comans EF, Senan S.
    J Thorac Oncol; 2012 Aug 01; 7(8):1271-5. PubMed ID: 22659960
    [Abstract] [Full Text] [Related]

  • 18. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D, Zheng X, Chen J, Liu G, Xu Y, Shen Y, Xie L, Zhao W, Jiang G, Fan M.
    Lung Cancer; 2015 Sep 01; 89(3):249-54. PubMed ID: 26118463
    [Abstract] [Full Text] [Related]

  • 19. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
    Kim HC, Ji W, Lee JC, Kim HR, Song SY, Choi CM, Korean Association for Lung Cancer, Korea Central Cancer Registry.
    Cancer Res Treat; 2021 Oct 15; 53(4):1033-1041. PubMed ID: 33592139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.